IPW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel
Application No.:	10/665,971 Group: 1642
Filed:	September 19, 2003 Examiner: Karen A. Canella
Confirmation No.:	5342
For:	METHODS OF TREATING NEURODEGENERATIVE INFLAMMATION WITH CHIMERIC ANTI-TNF ANTIBODIES

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:

3-4-05 Jane Morgan
Date Signature

JANE MORGAN
Typed or printed name of person signing certificate

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted under 37 CFR 1.97(b) before the mailing date of a first office action on the merits in the above-referenced application.

INFORMATION FROM RELATED LITIGATION

The Rockefeller University and Chiron Corporation have filed a complaint in The United States District Court For The Eastern District of Texas, Marshall Division, Civil Action No. 2-04CV-16, against Centocor, Inc., an assignee of this application, for infringement of U.S. Patent Nos: 6,309,640 and 6,419,927. The accused infringement relates to Centocor, Inc.'s product, REMICADE® infliximab. REMICADE® infliximab is also known as cA2, which is recited in the claims and specification in this application. The validity of this patent application is not at issue in the litigation. Nor is the validity of any related patents or patent applications at issue in this litigation.

Enclosed herewith is Form PTO-1449, citing U.S. Patent Nos: 6,309,640 and 6,419,927 and their related European application. Copies of these cited references (AC3, AD3 and AP7, respectively) are enclosed.

Applicants do not believe that this information is relevant or material to patentability. Applicants merely cite this information in an abundance of caution. Further, Applicants believe that this information is cumulative to References AA and AB, which were cited in the Information Disclosure Statement filed in this application on May 25, 2004. Reference AC3 is a continuation application of Reference AD3, which is, in turn, a continuation application of References AA and AB and thus have substantially identical disclosures and have the same priority date. In addition, Reference AP7 claims priority to the same priority applications as References AA and AB and has a substantially identical disclosure.

Applicants request that the information disclosed herein be made of record in this application. Applicants respectfully request that the Examiner return a copy of this Supplemental Information Disclosure Statement and acknowledge the information from the related litigation.

PHUONG GAMBO 12/12/06

Examiner Date

Method of payment:

[ ] A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.

[X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Deirdre E. Sanders

Deirdre E. Sanders
Registration No.: 42,122
Telephone: (978) 341-0036
Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated: March 4, 2005

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	APPLICATION NO.
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	0975.1005-036	10/665,971
May 19, 2004	FIRST NAMED INVENTOR: Junming Le, *et al.*	FILING DATE: September 19, 2003
(Use several sheets if necessary)	EXAMINER: Not Assigned	CONFIRMATION NO.: 5342 / GROUP: 1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	AA	4,603,106	07/29/1986	Cerami *et al.*
	AB	4,822,776	04/18/1989	Cerami *et al.*
	AC	5,658,570	08/19/1997	Newman *et al.*
	AD	5,750,105	05/12/1998	Newman *et al.*
	AE	5,231,024	07/27/93	Moeller *et al.*
	AF	5,223,395	06/29/1993	Gero
	AG	5,436,154	07/25/1995	Barbanti *et al.*
	AH	5,654,407	08/05/1997	Boyle *et al.*
	AI	5,700,788	12/23/1997	Mongelli *et al.*
	AJ	5,730,975	03/24/1998	Hotamisligil *et al.*
	AK	5,741,488	04/21/1998	Feldman *et al.*
	AA2	5,776,947	07/07/1998	Kroemer *et al.*
	AB2	6,015,558	01/18/2000	Hotamisligil *et al.*
	AC2	6,172,202 B1	01/09/2001	Marcucci *et al.*
	AD2	6,194,451 B1	02/27/2001	Alpegiani *et al.*
	AE2	5,360,716	11/01/1994	Ohmoto *et al.*
	AF2	5,888,511	03/30/1999	Skurkovich *et al.*
	AG2	5,958,413	09/28/1999	Anagnostopulos *et al.*
	AH2	5,993,833	11/30/1999	DeLarcharriere *et al.*
	AI2	5,342,613	08/30/1994	Creaven *et al.*
	AJ2	6,190,691 B1	02/20/2001	Mak
	AK2	4,816,567	03/28/1989	Cabilly *et al.*
	AA3	5,075,236	12/24/1991	Yone *et al.*
	AB3	5,959,087	09/28/1999	Rathjen *et al.*
	AC3			

EXAMINER	DATE CONSIDERED
	11/1/06

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 0975.1005-036	APPLICATION NO. 10/665,971
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Junming Le, *et al.*	FILING DATE September 19, 2003
May 19, 2004 (Use several sheets if necessary)	EXAMINER Not Assigned	CONFIRMATION NO. 5342 / GROUP 1642

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES	TRANSLATION NO
	AL	EP 0212489A2	03/04/1987	The Rockefeller University		
	AM	EP 0218868A2	04/22/1987	New York Blood Center, Inc.		
	AN	EP 0288 088 B1	03/09/1994	Teijin Limited		
	AO	EP 0308378 B1	11/30/1994	Yeda Research and Development Company Limited		
	AP	EP 0380068A1	08/01/1990	Molecular Therapeutics, Inc.		
	AQ	EP 0393438A2	10/24/1990	Boehringer Ingelheim International G.M.B.H.		
	AL2	EP 0398327 B1	03/15/1995	Yeda Research and Development Company Limited		
	AM2	EP 0412486 B1	11/30/1994	Yeda Research and Development Company Limited		
	AN2	EP 0433900 B1	09/20/1995	Yeda Research and Development Company Limited		
	AO2	EP 0526905A2	02/10/1993	Yeda Research and Development Company Limited		
	AP2	WO 91/02078	02/21/1991	Peptide Technology LTD		
	AQ2	WO 92/07076	04/30/1992	The Charing Cross Sunley Research Centre		
	AL3	WO 92/13095	08/06/1992	Synergen, Inc.		
	AM3	EP 0260610 B1	03/23/1988	BASF Aktiengesellschatt		
	AN3	WO 91/09967	07/11/1991	Celltech Limited		
	AO3	EP 0351789A2	01/24/1990	Chiron Corporation		
	AP3	EP 0350690A2	01/17/1990	BASF Aktiengesellschatt		
	AQ3	WO 90/00902	02/08/1990	Chiron Corporation		
	AL4	WO 92/11383	07/09/1992	Celltech Limited		
	AM4	WO 93/02108	02/04/1993	IDEC Pharmaceuticals Corporation		
	AN4	WO 92/16553	10/01/1992	New York University		

EXAMINER	DATE CONSIDERED
	12/12/06

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 0975.1005-036	APPLICATION NO. 10/665,971
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Junming Le, *et al.*	FILING DATE September 19, 2003
May 19, 2004 (Use several sheets if necessary)	EXAMINER Not Assigned	CONFIRMATION NO. 5342 / GROUP 1642

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES	TRANSLATION NO
M	AO4	WO 91/09967	07/11/1991	Celltech Limited		
	AP4	EP 0486526B2	05/27/1992	Peptech Limited		
	AQ4	EP 0512528 B1	11/11/1992	Yeda Research and Development Company Limited		
	AL5	EP 0351789 B1	01/24/1990	Chiron Corporation		
	AM5	EP 0453898 A2	10/30/1991	Bayer AG	X	
	AN5	EP 0585705 A1	03/09/1994	Miles Inc.		
	AO5	EP 0614984 A2	09/14/1994	Miles Inc.		
	AP5	WO 89/08460	09/21/1989	Celltech Limited		
	AQ5	WO 90/01950	03/08/1990	Celltech Limited		
	AL6	WO 91/04054	04/04/1991	Millar		
	AM6	WO 92/01472	02/06/1992	Celltech Limited		
	AN6	WO 93/11236	06/10/1993	Medical Research Council		
	AO6	WO 94/08609	04/28/1994	Dana Farber Cancer Institute, Inc.		
	AP6	WO 94/08619	04/28/1994	The Kennedy Institute of Rheumatology		
	AQ6	WO 92/01059	01/23/1992	Celltech Limited		
	AL7	02-227095	09/10/1990	Otsuka Pharmaceut CO LTD		
	AM7	61-047500	03/07/1986	RES DEV CORP OF JAPAN		
	AN7	DE 42 02 665 A1	07/29/1993	Schering AG Berlin und Bergkamen		
K	AO7	EP 0663836 B1	07/09/1997	The Kennedy Institute of Rheumatology		

EXAMINER	DATE CONSIDERED
[signature]	11/22/06

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 0975.1005-036	APPLICATION NO. 10/665,971	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Junming Le, *et al.*	FILING DATE September 19, 2003	
May 19, 2004 (Use several sheets if necessary)	EXAMINER Not Assigned	CONFIRMATION NO. 5342	GROUP 1642

		OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*
	AR	Beutler, B. *et al.*, "Identity of tumour necrosis factor and the macrophage-secreted factor cachectin," *Nature, 316*:552-554 (1985).
	AS	Beutler, B. *et al.*, "Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin," *Science, 229*:869-871 (1985).
	AT	Morrison, Sherie L., "Transfectomas Provide Novel Chimeric Antibodies," *Science, 229*:1202-1207 (1985).
	AU	Liang, Chi-Ming *et al.*, "Production and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor/Cachectin," *Biochem. & Biophy. Res. Comm., 137(2)*:847-854 (1986).
	AV	Hirai, Makoto *et al.*, "Production and characterization of monoclonal antibodies to human tumor necrosis factor," *J. of Immun. Methods, 96*:57-62 (1987).
	AW	Piguet, Pierre-Francois *et al.*, "Tumor Necrosis Factor/Cachectin is an Effector of Skin and Gut Lesions of the Acute Phase of Graft-vs.-Host Disease," *J. Exp. Med., 166*:1280-1289 (1987).
	AX	Meager, Anthony *et al.*, "Preparation and Characterization of Monoclonal Antibodies Directed Against Antigenic Determinants of Recombinant Human Tumour Necrosis Factor (rTNF)," *Hybridoma, 6(3)*:305-311 (1987).
	AY	Fendly, Brian M. *et al.*, "Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor," *Hybridoma, 6(4)*:359-370 (1987).
	AZ	Bringman, Timothy S. and Aggarwal, Bharat B., "Monoclonal Antibodies to Human Tumor Necrosis Factors Alpha and Beta: Applications for Affinity Purification, Immunoassays, and as Structural Probes," *Hybridoma, 6(5)*:489-507 (1987).
	AR2	Tracey, Kevin J. *et al.*, "Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia," *Nature, 330*:662-664 (1987).
	AS2	Nagai, M. *et al.*, "Antibody to tumor necrosis factor (TNF) reduces endotoxin fever," *Experientia, 44*:606-607 (1988).
	AT2	Shimamoto, Yoshinori *et al.*, "Monoclonal antibodies against human recombinant tumor necrosis factor: prevention of endotoxic shock," *Immunology Letters, 17*:311-318 (1988).

EXAMINER	DATE CONSIDERED
D Anne Gambel	12/12/06

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 0975.1005-036	APPLICATION NO. 10/665,971
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Junming Le, *et al.*	FILING DATE September 19, 2003
May 19, 2004	EXAMINER Not Assigned	CONFIRMATION NO. 5342 / GROUP 1642
(Use several sheets if necessary)		

		OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*
	AU2	Di Giovine, Francesco, S. *et al.*, "Tumour necrosis factor in synovial exudates," *Annals of the Rheumatic Diseases, 47*:768-772 (1988).
	AV2	Collins, M.S. *et al.*, "Immunoprophylaxis of Polymicrobic Cellulitis with a Human Monoclonal Antibody Against Lipopolysaccharide Antigen of Pseudomonas aeruginosa," Abstract E-63, *Abstracts of Annual Meeting 1989.*
	AW2	Exley, A.R. *et al.*, "Monoclonal Antibody (Mab) to Recombinant Human Tumour Necrosis Factor (rhTNF) in the Prophylaxis and Treatment of Endotoxic Shock in Cynomolgus Monkeys," *Medical Research Society*, Abstract 184, p. 50 (1989).
	AX2	Cross, A.S. *et al.*, "Pretreatment with Recombinant Murine Tumor Necrosis Factor α/Cachectin and Murine Interleukin 1 α Protects Mice from Lethal Bacterial Infection," *J. of Exp. Med., 169*:2021-2027 (1989).
	AY2	Engelmann, Hartmut *et al.*, "A Tumor Necrosis Factor-binding Protein Purified to Homogeneity from Human Urine Protects Cells from Tumor Necrosis Factor Toxicity," *J. of Bio. Chem., 264(20)*:11974-11980 (1989).
	AZ2	Silva, Ayona T. *et al.*, "Prophylactic and Therapeutic Effects of a Monoclonal Antibody to Tumor Necrosis Factor-α in Experimental Gram-Negative Shock," *J. of Infectious Diseases, 162*:421-427 (1990).
	AR3	Opal, Steven M. *et al.*, "Efficacy of a Monoclonal Antibody Directed Against Tumor Necrosis Factor in Protecting Neutropenic Rats from Lethal Infection with *Pseudomonas aeruginosa*," *J. of Infectious Diseases, 161*:1148-1152 (1990).
	AS3	Tavernier, Jan *et al.*, "Analysis of the Structure-Function Relationship of Tumour Necrosis Factor. Human/Mouse Chimeric TNF Proteins: General Properties and Epitope Analysis," *J. Mol. Biol., 211*:493-501 (1990).
	AT3	Lucas, R. *et al.*, "Generation and characterization of a neutralizing rat anti-rm TNF-α monoclonal antibody," *Immunology, 71*:218-223 (1990).
	AU3	Hinshaw, L.B. *et al.*, "Survival of Primates in LD_{100} Septic Shock Following Therapy with Antibody to Tumor Necrosis Factor (TNFα)," *Circulatory Shock, 30*:279-292 (1990).
	AV3	Nophar, Yaron *et al.*, "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type 1 TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor," *The EMBO Journal, 9(10)*:3269-3278 (1990).

EXAMINER	DATE CONSIDERED
Phillip Gambel	11/21/06

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 0975.1005-036	APPLICATION NO. 10/665,971
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Junming Le, *et al.*	FILING DATE September 19, 2003
May 19, 2004	EXAMINER Not Assigned	CONFIRMATION NO. 5342 / GROUP 1642
(Use several sheets if necessary)		

		OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*
	AW3	Engelmann, Hartmut *et al.*, "Two Tumor Necrosis Factor-binding Proteins Purified from Human Urine," *J. of Bio. Chem., 265(3)*:1531-1536 (1990).
	AX3	Verhoef, J. and Torensma, R., "Prospects for Monoclonal Antibodies in the Diagnosis and Treatment of Bacterial Infections," *Eur. J. Clin. Microbiol. Dis., 9(4)*:247-250 (1990).
	AY3	Loetscher, Hansruedi *et al.*, "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor," *Cell, 61*:351-359 (1990).
	AZ3	Schall, Thomas J. *et al.*, "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor," *Cell, 61*:361-370 (1990).
	AR4	Akama, Hideto *et al.*, "Mononuclear Cells Enhance Prostaglandin E_2 Production of Polymorphonuclear Leukocytes via Tumor Necrosis Factor α," *Biochemical and Biophysical Research Comm., 168(2)*:857-862 (1990).
	AS4	Exley, A.R. *et al.*, "Monoclonal antibody to TNF in severe septic shock," *The Lancet, 335*:1275-1277 (1990).
	AT4	Möller, Achim *et al.*, "Monoclonal Antibodies to Human Tumor Necrosis Factor α: *In Vitro* and *In Vivo* Application," *Cytokine, 2(3)*:162-169 (1990).
	AU4	Ruddle, Nancy H. *et al.*, "An Antibody to Lymphotoxin and Tumor Necrosis Factor Prevents Transfer of Experimental Allergic Encephalomyelitis," *J. Exp. Med., 172*:1193-1200 (1990).
	AV4	Galloway, Cynthia J. *et al.*, "Monoclonal anti-tumor necrosis factor (TNF) antibodies protect mouse and human cells from TNF cytotoxicity," *J. of Immunological Methods, 140*:37-43 (1991).
	AW4	Waldmann, Thomas A., "Monoclonal Antibodies in Diagnosis and Therapy," *Science, 252*:1657-1662 (1991).
	AX4	Aderka, Dan *et al.*, "The Possible Role of Tumor Necrosis Factor (TNF) and Its Natural Inhibitors, The Soluble-TNF Receptors, In Autoimmune Diseases," *Israel J. Med. Sci., 28(2)*:126-130 (1992).
	AY4	Pennington, James, "TNF: Therapeutic Target in Patients with Sepsis," *ASM News, 58(9)*:479-482 (1992).
	AZ4	Harris, William J. and Emery, Steven, "Therapeutic antibodies - the coming of age," *TBTECH, 11*:42-44 (1993).

EXAMINER	DATE CONSIDERED
Phillip Gambel	11/14/06

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 0975.1005-036	APPLICATION NO. 10/665,971	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Junming Le, *et al.*	FILING DATE September 19, 2003	
May 19, 2004	EXAMINER Not Assigned	CONFIRMATION NO. 5342	GROUP 1642
(Use several sheets if necessary)			

		OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*
	AR5	Parrillo, Joseph E., "Pathogenetic Mechanisms of Septic Shock," *N.E. Journal of Medicine, 328(20)*:1471-1477 (1993).
	AS5	Aggarwal, Bharat B. *et al.*, "Human Tumor Necrosis Factor Production, Purification and Characterization," *J. of Biol. Chem., 260(4)*:2345-2354 (1985).
	AT5	Beutler, B. *et al.*, "Purification of Cachectin, A Lipoprotein Lipase-Suppressing Hormone Secreted by Endotoxin-induced RAW 264.7 Cells," *J. Exp. Med., 161*:984-995 (1985).
	AU5	Echtenacher, Bernd *et al.*, "Requirement of Endogenous Tumor Necrosis Factor/Cachectin for Recovery from Experimental Peritonitis," *J. of Immunology, 145(11)*:3762-3766 (1990).
	AV5	Smith, Craig R., "Human and Chimeric Antibodies to LPS and TNF," 4Abstract, *Endotoxemia & Sepsis Conference* (1991).
	AW5	Bodmer, Mark, "Humanized Antibodies for Anti-TNF Therapy," Abstract, *Endotoxemia & Sepsis Conference* (1991).
	AX5	Genebank Accession, No. N90300 (November 1, 1989).
	AY5	Genebank Accession, No. M32046 (June 15, 1990).
	AZ5	Paulus, H., "Preparation and Biomedical Applications of Bispecific Antibodies", *Behring Inst. Mitt*, No.78:118-132 (1985).
	AR6	Whittle, Nigel, *et al.*, "Construction and Expression of a CDR-Grafted Anti-TNF Antibody," *J. Cell Biochem.*, Supl. 13A:96 (1989).
	AS6	Gorman, S.D. and Clark, M.R., "Humanisation of monoclonal antibodies for therapy," *Sem. Immunol.*, 2:457-466 (1990).
	AT6	Starnes, H. Fletcher, Jr., *et al.*, "ANTI-IL-6 Monoclonal Antibodies Protect Against Lethal *Escherichia Coli* Infection and Lethal Tumor Necrosis Factor∝ Challenge in Mice," *J. Immunol.*, 145:4185-4191 (1990).
	AU6	Duncombe, Andrew S. *et al.*, "Tumor Necrosis Factor Mediates Autocrine Growth Inhibition in a Chronic Leukemia," *J. Immunol.*, 143:3828-3834 (1989).

EXAMINER	DATE CONSIDERED
	12/12/06

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 0975.1005-036	APPLICATION NO. 10/665,971	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Junming Le, *et al.*	FILING DATE September 19, 2003	
May 19, 2004	EXAMINER Not Assigned	CONFIRMATION NO. 5342	GROUP 1642
(Use several sheets if necessary)			

		OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*
	AV6	Aderka, Dan *et al.*, "IL-6 Inhibits Lipopolysaccharide-Induced tumor Necrosis Factor Production in Cultured Human Monocytes, U937 Cells, and in Mice," *J. Immunol.*, 143:3517-3523 (1989).
	AW6	Aderka, Dan, "Role of Tumor Necrosis Factor in the Pathogenesis of Intravascular Coagulopathy of Sepsis: Potential New Therapeutic Implications," *Isr. J. Med. Sci.*, 27:52-60 (1991).
	AX6	Lassalle, Ph., *et al.*, "Potential Implicaton of Endothelial Cells in Bronchial Asthma," *Int. Arch Allergy Appl. Immunol.*, 94:233-238 (1991).
	AY6	Fong, Yuman and Lowry, Stephen F., "Tumor Necrosis Factor in the Pathophysiology of Infection and Sepsis," *Clin. Immunol. Immunopathol.*, 55:157-170 (1990).
	AZ6	Eck, Michael J. and Sprang, Stephen R., "The Structure of Tumor Necrosis Factor-∝ at 2.6 Å Resolution," *J. Biol. Chem.*, 264:17595-17605 (1989).
	AR7	Gillies, Stephen D. *et al.*, "High-level expression of chimeric antibodies using adapted cDNA variable region cassettes," *J. Immunol. Methods*, 125:191-202 (1989).
	AS7	Kameyama, Koh-zoh, *et al.*, "Convenient plasmid vectors for construction of chimeric mouse/human antibodies," *FEBS Lett.*, 244:301-306 (1989).
	AT7	Hayashi, H. *et al.*, "An Enzyme-linked Immunosorbent Assay for Recombinant Human Tumor Necrosis Factor Using Monoclonal Antibody," *Recent Adv. Chemother.*, 820-821 (1985).
	AU7	Hirai, Makoto *et al.*, "Production and characterization of monoclonal antibodies to human tumor necrosis factor," *J. Immunol. Methods*, 96:57-62 (1987).
	AV7	Sunahara, N. *et al.*, "Simple enzyme immunoassay methods for recombinant human tumor necrosis factor ∝ and its antibodies using a bacterial cell wall carrier," *J. Immunol. Methods*, 109:203-214 (1988).
	AW7	Oliff, A., *et al.*, "Tumors Secreting Human TNF/Cachectin Induce Cachexia in Mice," *Cell*, 50:555-563 (1987).
	AX7	Mule, J.J., *et al.*, "Antitumor Activity of Recombinant Interleukin 6 in Mice," *The Journal of Experimental Medicine*, 171:629-636 (1990).
	AY7	Luettig, B., *et al.*, "Evidence For The Existence Of Two Forms Of Membrane Tumor Necrosis Factor: An Integral Protein And A Molecule Attached To Its Receptor," *The Journal of Immunology*, 143:4034-4038 (1989).

EXAMINER	DATE CONSIDERED
[signature]	12/14/06

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 0975.1005-036	APPLICATION NO. 10/665,971	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Junming Le, *et al.*	FILING DATE September 19, 2003	
May 19, 2004	EXAMINER Not Assigned	CONFIRMATION NO. 5342	GROUP 1642
(Use several sheets if necessary)			

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*		
M	AZ7	Barbuto, J.A.M., *et al.*, "Production of neutralizing antibodies to tumor necrosis factor by human tumor-infiltrating B lymphocytes," *Proceedings of the American Association for Cancer Research*, 34:487, Abstract 2904, (1993).
	AR8	Bendtzen, K., *et al.*, "Auto-Antibodies To IL-1α and TNFα In Normal Individuals And In Infectious And Immunoinflammatory Disorders," *The Physiological and Pathological Effects of Cytokines*, 10B:447-452 (1990).
	AS8	Fomsgaard, A., *et al.*, "Auto-Antibodies To Tumour Necrosis Factor α In Healthy Humans And Patients With Inflammatory Diseases And Gram-Negative Bacterial Infections," *Scand. J. Immunol.*, 30:219-223 (1989).
	AT8	James, K. and Bell, G.T., "Human Monoclonal Antibody Production Current Status And Future Prospects," *Journal of Immunological Methods*, 100:5-40 (1987).
	AU8	Alberts, B. *et al.*, Molecular Biology of the Cell, Garland Publishing Inc., pp 182-183 (1983).
	AV8	Simpson, S.Q., *et al.*, "Role Of Tumor Necrosis Factor In Sepsis And Acute Lung Injury," *Critical Care Clinics*, 5:27-47 (1989).
	AW8	Bendtzen, K., *et al.*,"Native inhibitors (autoantibodies) of IL-1α and TNF," *Immunology Today*, 10(7):222 (1989).
	AX8	Davenport, C., *et al.*, "Stimulation Of Human B Cells Specific For Candida Albicans For Monoclonal Antibody Production," *FEMS Microbiol. Immunol*, 4(6):335-343 Abstract (1992).
	AY8	Pennica, D., *et al.*, "Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin," *Nature*, 312(20/27):724-729 (1984).
	AZ8	Gray, P.W., *et al.*, "Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity," *Nature*, 312(20/27):721-724 (1984).
	AR9	Petersen, C.M., *et al.*, "Bioactive human recombinant tumor necrosis factor-α: an unstable dimer?*," *Eur. J. Immunol.*, 19:1887-1894 (1989).
K	AS9	Smith, C. A., *et al.*, "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins," *Science*, 248:1019-1023 (1990).

EXAMINER	DATE CONSIDERED
Phillip Gambel	12/21/06

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 0975.1005-036	APPLICATION NO. 10/665,971	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Junming Le, *et al.*	FILING DATE September 19, 2003	
May 19, 2004	EXAMINER Not Assigned	CONFIRMATION NO. 5342	GROUP 1642
(Use several sheets if necessary)			

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*		
	AT9	Brennan, F.M., *et al.*, "Inhibitory Effect Of TNFα Antibodies On Synovial Cell Interleukin-1 Production In Rheumatoid Arthritis," *The Lancet*, 244-247 (1989).
	AU9	Hahn, T., *et al.*, "Use of monoclonal antibodies to a human cytotoxin for its isolation and for examining the self-induction of resistance to this protein," *Proc. Natl. Acac. Sci. USA* 82:3814-3818 (1985).
	AV9	Grau, G.E., *et al.*, "Tumor Necrosis Factor (Cachectin) as an Essential Mediator in Murine Cerebral Malaria," *Science*, 237:1210-1212 (1987).
	AW9	Barbanti, E., *et al.*, "A high-affinity neutralizing anti-human TNF-alpha monoclonal antibody that cross-reacts with human TNF–beta," *Abstracts*, March 6th-9th (1991).
	AX9	Jones, E.Y., *et al.*, "Structure of tumour necrosis factor," *Nature*, 338:225-228 (1989).
	AY9	Clark, W. R., "Types of Antibody Reactions," In *The Experimental Foundations of Modern Immunology*, (NY: John Wiley & Sons, Inc.) 4th Ed., pp 143-155 (1991).
	AZ9	Beutler, B., *et al.*, "Cachectin and tumour necrosis factor as two sides of the same biological coin," *Nature*, 320:584-588 (1986).
	AR10	Folks, T. M., *et al.*, "Tumor Necrosis factor α induces expression of human immunodeficiency virus in a chronically infected T-cell clone," *Proc. Natl. Acad. Sci. USA*, 86:2365-2358 (1989).
	AS10	Hird, V., *et al.*, "Immunotherapy with Monoclonal Antibodies," In *Genes and Cancer* (John Wiley & Sons, Ltd.)(1990).
	AT10	Rhein, R., "Another sepsis drug down-Immunex' TNF receptor," *Biotechnology Newswatch*, Monday, October 4, 1993, pp. 1,3.
	AU10	Boyle, P., *et al.*, "A Novel Monoclonal Human IgM Autoantibody which Binds Recombinant Human and Mouse Tumor Necrosis Factor-α," *Cellular Immunology*, 152:556-568 (1993).
	AV10	Boyle, P., *et al.*, "The B5 Monoclonal Human Autoantibody Binds to Cell Surface TNFα on Human Lymphoid Cells and Cell Lines and Appears to Recognize a Novel Epitope," *Cellular Immunology*, 152:569-581 (1993).

EXAMINER	DATE CONSIDERED
	11/1/06

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	APPLICATION NO.	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	0975.1005-036	10/665,971	
	FIRST NAMED INVENTOR	FILING DATE	
May 19, 2004	Junming Le, *et al.*	September 19, 2003	
(Use several sheets if necessary)	EXAMINER	CONFIRMATION NO.	GROUP
	Not Assigned	5342	1642

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*		
	AW10	Sheehan, K.C.F., *et al.*, "Generation And Characterization Of Hamster Monoclonal Antibodies That Neutralize Murine Tumor Necrosis Factors," *The Journal of Immunology*, 142(11):3884-3893 (1989).
	AX10	Jacob, C.O., *et al.*, "Tumour necrosis factor-α in murine autoimmune 'lupus' nephritis," *Nature*, 331:356-358 (1988).
	AY10	Mateo, C. *et al.*, "Removal of Amphipathic Epitopes from Genetically Engineered Antibodies: Production of Modified Immunoglobulins with Reduced Immunogenicity", *Hybridoma*, 19(6):463-471 (2000).
	AZ10	Paul, W.E. (Ed.), *Fundamental Immunology*, 3rd Edition, Pub. Raven Press Ltd., pp. 292-293 (1993).
	AR11	Beck, J., *et al.*, "Increased Production of Interferon Gamma and Tumor Necrosis Factor Precedes Clinical Manifestation in Multiple Sclerosis: Do Cytokines Trigger Off Exacerbations?," Acta. Neurol. Scand., 78: 318-323 (1988).
	AS11	Beck, J., *et al.*, "Increased Production of TNF-α in Multiple Sclerosis," Immunobiology, 175(1-2): 91-92 (1987) Abstract.
	AT11	Selmaj, K. *et al.*, "Tumor Necrosis Factor Mediates Myelin Damage in Organotypic Cultures of Nervous Tissue," *Neuroimmunology*, 16(1): 159 (1987) Abstract.
	AU11	Pardridge, W.M., "New approaches to drug delivery through the blood-brain barrier," *Trends in Biotechnology*, 12(6): 239-245 (1994).
	AV11	Van Oosten, B.W., *et al.*, "Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2," *Neurology*, 47(6):1531-1534 (1996) Abstract.
	AW11	Van Oosten, B.W., *et al.*, "Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: Results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial," *Neurology*, 49(2):351-357 (1997) Abstract.
	AX11	Arnason, B.G.W., "TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study," *Neurology*, 53(3):457-465 (1999) Abstract.
	AY11	Kassiotis G. and Kollias G., "Uncoupling the Proinflammatory from the Immunosuppressive Properties of Tumor Necrosis Factor (TNF) at the p55 TNF Receptor Level: Implications for Pathogenesis and Therapy of Autoimmune Demyelination," *J. Exp. Med.*, 193(4):427-434 (2001).

EXAMINER	DATE CONSIDERED
	11/1/06

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	APPLICATION NO.	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	0975.1005-036	10/665,971	
	FIRST NAMED INVENTOR	FILING DATE	
May 19, 2004	Junming Le, *et al.*	September 19, 2003	
(Use several sheets if necessary)	EXAMINER	CONFIRMATION NO.	GROUP
	Not Assigned	5342	1642

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*		
	AZ11	Selmaj, K, *et al.*, "Anti-Tumor Necrosis Factor Therapy Abrogates Autoimmune Demyelination," *Ann. Neurol. (30)*:694-700 (1991).

EXAMINER	DATE CONSIDERED

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 0975.1005-036	APPLICATION NO. 10/665,971
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Junming Le	FILING DATE September 19, 2003
March 4, 2005 (Use several sheets if necessary)	EXAMINER Karen A. Canella	CONFIRMATION NO. 5342 / GROUP 1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
KC	AC3	US 6,309,640 B1	10/30/2001	Cerami *et al.*
KC	AD3	US 6,419,927 B1	07/16/2002	Cerami *et al.*

EXAMINER	DATE CONSIDERED
	11/10/06

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	APPLICATION NO.
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION	0975.1005-036	10/665,971
	FIRST NAMED INVENTOR: Junming Le	FILING DATE: September 19, 2003
March 4, 2005	EXAMINER: Karen A. Canella	CONFIRMATION NO.: 5342
(Use several sheets if necessary)		GROUP: 1642

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES	TRANSLATION NO
	AP7	EP 0 101 681 B1	12/14/1994	The Rockefeller University		

EXAMINER	DATE CONSIDERED
[signature]	12/12/05

[X] the enclosed English language abstracts for AQ, AM3, AP3, AM5, AL7, AM7 and AN7.

[X] Applicant requests that the following pending applications be considered:

Examiner's Initials

M

U.S. Patent Application No. 09/756,398, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed January 8, 2001, Docket No.: 0975.1005-006.

U.S. Patent Application No. 09/756,301, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed January 8, 2001, Docket No.: 0975.1005-008.

U.S. Patent Application No. 09/766,535, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed January 18, 2001, Docket No.: 0975.1005-010.

U.S. Patent Application No. 09/897,724, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed July 2, 2001, Docket No.: 0975.1005-012.

U.S. Patent Application No. 09/927,703, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed August 10, 2001, Docket No.: 0975.1005-013.

U.S. Patent Application No. 10/010,229, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed December 7, 2001, Docket No.: 0975.1005-014.

U.S. Patent Application No. 10/043,450, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed January 10, 2002, Docket No.: 0975.1005-015.

U.S. Patent Application No. 10/044,534, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed January 10, 2002, Docket No.: 0975.1005-016.

U.S. Patent Application No. 10/043,432, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed January 10, 2002, Docket No.: 0975.1005-017.

U.S. Patent Application No. 10/043,436, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed January 10, 2002, Docket No.: 0975.1005-018.

U.S. Patent Application No. 10/176,460, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed June 20, 2002, Docket No.: 0975.1005-019.

U.S. Patent Application No. 10/187,121, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed June 28, 2002, Docket No.: 0975.1005-020.

U.S. Patent Application No. 10/186,559, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed June 28, 2002, Docket No.: 0975.1005-021.

12/22/06

U.S. Patent Application No. 10/198,845, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed July 18, 2002, Docket No.: 0975.1005-022.

U.S. Patent Application No. 10/200,795, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed July 22, 2002, Docket No.: 0975.1005-023.

U.S. Patent Application No. 10/208,145, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed July 29, 2002, Docket No.: 0975.1005-024.

U.S. Patent Application No. 10/227,488, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed August 23, 2002, Docket No.: 0975.1005-025.

U.S. Patent Application No. 10/319,011, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed December 12, 2002, Docket No.: 0975.1005-029.

U.S. Patent Application No. 10/371,443, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed February 21, 2003, Docket No.: 0975.1005-031.

U.S. Patent Application No. 10/371,962, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed February 21, 2003, Docket No.: 0975.1005-032.

U.S. Patent Application No. 10/371,961, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed February 21, 2003, Docket No.: 0975.1005-033.

U.S. Patent Application No. 10/379,866, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed March 4, 2003, Docket No.: 0975.1005-034.

U.S. Patent Application No. 10/774,118, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel, filed February 6, 2004 Docket No.: 0975.1005-038.

Examiner 11/24/06
Date

[ ] A copy of the above-cited applications, including the current claims, is enclosed.

[X] The specifications for the above cited co-pending applications are substantially identical to the present specification (10/665,971) and the specification of the priority application, U.S. Application No. 09/756,398, to which priority under 35 U.S.C. 120 is claimed. Therefore, only copies of the current claims for these applications are enclosed. Copies of the specifications of the co-pending applications will be provided upon request.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.